» Articles » PMID: 28421341

Insufficient Activation of Akt Upon Reperfusion Because of Its Novel Modification by Reduced PP2A-B55α Contributes to Enlargement of Infarct Size by Chronic Kidney Disease

Overview
Date 2017 Apr 20
PMID 28421341
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic kidney disease (CKD) increases myocardial infarct size by an unknown mechanism. Here we examined the hypothesis that impairment of protective PI3K-PDK1-Akt and/or mTORC-Akt signaling upon reperfusion contributes to CKD-induced enlargement of infarct size. CKD was induced in rats by 5/6 nephrectomy (SNx group) 4 weeks before myocardial infarction experiments, and sham-operated rats served as controls (Sham group). Infarct size as a percentage of area at risk after ischemia/reperfusion was significantly larger in the SNx group than in the Sham group (56.3 ± 4.6 vs. 41.4 ± 2.0%). In SNx group, myocardial p-Akt-Thr308 level at baseline was elevated, and reperfusion-induced phosphorylation of p-Akt-Ser473, p-p70s6K and p-GSK-3β was significantly suppressed. Inhibition of Akt-Ser473 phosphorylation upon reperfusion by Ku-0063794 significantly increased infarct size in the Sham group but not in the SNx group. There was no difference between the two groups in activities of mTORC2 and PDK1 and protein level of PTEN. However, the PP2A regulatory subunit B55α, which specifically targets Akt-Thr308, was reduced by 24% in the SNx group. Knockdown of B55α by siRNA increased baseline p-Akt-Thr308 and blunted Akt-Ser473 phosphorylation in response to insulin-like growth factor-1 (IGF-1) in H9c2 cells. A blunted response of Akt-Ser473 to IGF-1 was also observed in HEK293 cells transfected with a p-Thr308-mimetic Akt mutant (T308D). These results indicate that increased Akt-Thr308 phosphorylation by down-regulation of B55α inhibits Akt-Ser473 phosphorylation upon reperfusion in CKD and that the impaired Akt activation by insufficient Ser473 phosphorylation upon reperfusion contributes to infarct size enlargement by CKD.

Citing Articles

Myocardial overexpression of protein phosphatase 2A-B56α improves resistance against ischemia-reperfusion injury.

Herting J, Berg A, Hadova K, Heinick A, Konig S, Kuhlmann M J Mol Cell Cardiol Plus. 2025; 3():100030.

PMID: 39803363 PMC: 11708487. DOI: 10.1016/j.jmccpl.2022.100030.


Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms.

Miura T, Sato T, Yano T, Takaguri A, Miki T, Tohse N Cardiovasc Drugs Ther. 2022; 37(6):1175-1192.

PMID: 35150385 DOI: 10.1007/s10557-022-07321-3.


Identification of hub genes and transcription factor-miRNA-mRNA pathways in mice and human renal ischemia-reperfusion injury.

Ke P, Qian L, Zhou Y, Feng L, Zhang Z, Zheng C PeerJ. 2021; 9:e12375.

PMID: 34754625 PMC: 8555504. DOI: 10.7717/peerj.12375.


PP2A protects podocytes against Adriamycin-induced injury and epithelial-to-mesenchymal transition via suppressing JIP4/p38-MAPK pathway.

Lu Z, Zhu X, Ye Y, Fu H, Mao J Cytotechnology. 2021; 73(5):697-713.

PMID: 34629746 PMC: 8492838. DOI: 10.1007/s10616-021-00484-1.


Role of protein phosphatase 2A in kidney disease (Review).

Shao L, Ma Y, Fang Q, Huang Z, Wan S, Wang J Exp Ther Med. 2021; 22(5):1236.

PMID: 34539832 PMC: 8438693. DOI: 10.3892/etm.2021.10671.